EMA Application withdrawn: Graspa — ERYTECH Pharma S.A.

View source ↗

Summary

EMA has withdrawn the application for Graspa by ERYTECH Pharma S.A., in the therapeutic area of Precursor Cell Lymphoblastic Leukemia-Lymphoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Precursor Cell Lymphoblastic Leukemia-lymphoma

Drugs mentioned

• GRASPA (L-asparaginase encapsulated in red blood cells)

Snippet

Status: Application withdrawn. Therapeutic area: Precursor Cell Lymphoblastic Leukemia-Lymphoma. MAH: ERYTECH Pharma S.A.. Decision date: 16/12/2016. Orphan medicine